Treatment Horizons

The Deeper End of the Ocean Host restrictive factors create research excitement by Mariel Selbovitz, MPH, and David Miller The doors on viral host restrictive factors (HRFs),...

Warts & All An immunotherapy candidate seeks to address complications from HPV by Chael Needle Human papillomavirus (HPV) is the most common sexually transmitted infection, but, according...

Treatment Horizons by Chael Needle Surpassing Expectations ViiV Healthcare introduces its first FDA-approved agent ViiV Healthcare is exclusively devoted to the treatment of HIV disease, and the...

Treatment Horizons by Chael Needle Fully Personalized An immunotherapy candidate stimulates T-cell responses via patient-specific antigens Previous studies have established immunotherapy candidate AGS-004, both as a single...

Treatment Horizons by Chael Needle A nonprofit creates a new support system for the uninsured Joining Merck and ViiV Healthcare, Gilead Sciences is now supporting and...

Treatment Horizons by Chael Needle Hill & Mountain? Weakened federal support of HIV/AIDS services puts our health at risk President Obama’s fiscal year 2014 budget plan includes...

Hide and Seek Led by Dr. Daria Hazuda, researchers tackle HIV latency with HDAC inhibitors by Chael Needle With all the talk around viral suppression, it may...

Sun Blocked A new study examines non-melanoma skin cancers & HIV by Chael Needle In the pre-HAART era, an AIDS diagnosis or even an HIV-positive diagnosis illuminated...

A newly approved anti-diarrheal agent seeks to counter side effects of HAART by Chael Needle Recently, the FDA approved Fulyzaq (crofelemer) 125 mg delayed-release tablets for...

Stronger Punch? Monoclonal antibodies provide new hope for easier dosing by Jeannie Wraight With multi-drug, once-a-day therapies now available for use, the push for additional easier to...